Overcoming PARP Inhibitor and Platinum Resistance with WEE1 Inhibitors in Ovarian Cancer
Poly (ADP-ribose) polymerase inhibitors (PARPi) have transformed the treatment of high-grade epithelial ovarian cancer (EOC), with demonstrated efficacy in the recurrent as well as newly diagnosed disease. However, women with EOC inevitably acquire resistance to both platinum chemotherapy and PARPi....
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2021-10-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2021.09.047 |